Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether orally administered DS107 (1g and 2g doses)
is effective in the treatment of moderate to severe atopic dermatitis.
Oral DS107 capsules will be administered for 8 weeks and will be compared against placebo.
The study will enroll approximately 300 subjects.